EHA 2022
Lisaftoclax induced responses in patients with a variety of relapsed/refractory malignancies, including NHL and CLL.
In the study, 11 patients with relapsed/refractory diffuse LBCL were infused with anbal-cel.
The ORR was 96%, including 92% at the level of VGPR, and the MRD negativity rate was 62%...
Advertisement
Among 37 evaluable patients, the ORR was 78%, and 27 patients had a VGPR or better...
A phase III trial of magrolimab plus azacitidine versus standard of care in TP53-mutated AML is currently ongoing.
Of 23 patients, three achieved complete remission and 15 achieved complete remission with incomplete hematological recovery.
Advertisement
Epcoritamab is a subcutaneous CD3/CD20 bispecific antibody that induces anti-tumor activity across B-cell NHL subtypes.
The phase III GALLIUM study confirmed obinutuzumab plus chemotherapy as a standard of care for first-line follicular lymphoma
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.